Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.52 |
| ▸ | ARG2 | P78540 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | BHMT | Q93088 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14302976 | 0.84 | GRIK1 (0.43) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL27552293 | 0.84 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL69149 | 0.84 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL1848592 | 0.84 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL18788686 | 0.84 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL9236855 | 0.84 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL6762355 | 0.84 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL20854 | 0.84 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL2781165 | 0.84 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36933 | 0.83 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683055-B2 | Lanthionine-related compounds for the treatment of inflammatory diseases | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070197515-A1 | LANTHIONINE-RELATED COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2007-08-23 | — | — | US | disclosed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | ARG1 3068/4885ARG2 304/4885NOS2 2542/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | ARG1 2990/4885ARG2 471/4885NOS2 2879/4885 |
| US-20070197515-A1 | LANTHIONINE-RELATED COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | SLC7A11, AADAT, TSPO | ARG1 1529/4885ARG2 784/4885NOS2 257/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | ARG1 2990/4885ARG2 471/4885NOS2 2879/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | ARG1 2990/4885ARG2 471/4885NOS2 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.